Skip to main content
Top
Published in: Pediatric Nephrology 5/2007

01-05-2007 | Editorial Commentary

Diagnosis of Alport syndrome without biopsy?

Author: Marie Claire Gubler

Published in: Pediatric Nephrology | Issue 5/2007

Login to get access

Abstract

Alport syndrome (AS) is genetically heterogeneous. The gene COL4A5 is mutated in the more frequent X-linked dominant form of the disease whereas COL4A3 or COL4A4 are mutated in the autosomal recessive and dominant forms. Diagnosis of AS and determination of the mode of transmission are important because of the differences in prognosis and genetic counselling attached to these different forms. Recently, promising results have been obtained in Col4a3-null mice, an animal model for AS, with different therapeutic trials when administered early in the course of the disease, an additional reason for making early diagnosis of AS in children. Since the identification of the molecular basis of the disease, mutation screening is theoretically the best diagnostic approach, avoiding the use or renal or skin biopsy. However, for many reasons linked to the genetic heterogeneity of the disease, the large size of the three genes and the random distribution of the mutations all along these huge genes, this method is tedious, expensive and time consuming. Moreover, its sensitivity is reduced. For these reasons, evaluation of the expression of type IV collagen chains in the skin, and if necessary in the renal basement membrane, remains a useful tool for AS diagnosis. At this time, the indication for these different approaches, which are not mutually exclusive but complementary, depends on the patient clinical presentation and family history.
Literature
1.
go back to reference Feingold J, Bois E, Chompret A, Broyer M, Gubler MC, Grünfeld JP (1985) Genetic heterogenerity of Alport syndrome. Kidney Int 27:672–677CrossRefPubMed Feingold J, Bois E, Chompret A, Broyer M, Gubler MC, Grünfeld JP (1985) Genetic heterogenerity of Alport syndrome. Kidney Int 27:672–677CrossRefPubMed
2.
go back to reference Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG (2003) Alport’s syndrome, Goodpasture’s syndrome, and type IV collagen. New Engl J Med 348:2543–2556CrossRefPubMed Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG (2003) Alport’s syndrome, Goodpasture’s syndrome, and type IV collagen. New Engl J Med 348:2543–2556CrossRefPubMed
3.
go back to reference Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A, Weber M, Gross O, Netzer KO, Flinter F, Pirson Y, Verelen C, Wieslander J, Persson U, Tryggvason K, Martin P, Hertz JM, Schröder C, Sanak M, Krejcova S, Carvalho MF, Saus J, Antignac C, Smeets H, Gubler MC (2000) X-linked Alport syndrome. Natural history in 195 families and genotype-phenotype correlations in males. J Am Soc Nephrol 11:649–657PubMed Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A, Weber M, Gross O, Netzer KO, Flinter F, Pirson Y, Verelen C, Wieslander J, Persson U, Tryggvason K, Martin P, Hertz JM, Schröder C, Sanak M, Krejcova S, Carvalho MF, Saus J, Antignac C, Smeets H, Gubler MC (2000) X-linked Alport syndrome. Natural history in 195 families and genotype-phenotype correlations in males. J Am Soc Nephrol 11:649–657PubMed
4.
go back to reference Flinter FA, Cameron JS, Chantler C, Houston I, Bobrow M (1988) Genetics of classic Alport’s syndrome. Lancet 2:1005–1007CrossRefPubMed Flinter FA, Cameron JS, Chantler C, Houston I, Bobrow M (1988) Genetics of classic Alport’s syndrome. Lancet 2:1005–1007CrossRefPubMed
6.
go back to reference Slajpah M, Meglic A, Furlan P, Glavac D (2005) The importance of non-invasive genetic analysis in the initial dignostics of Alport syndrome in young patients. Pediatr Nephrol 20:1260–1264CrossRefPubMed Slajpah M, Meglic A, Furlan P, Glavac D (2005) The importance of non-invasive genetic analysis in the initial dignostics of Alport syndrome in young patients. Pediatr Nephrol 20:1260–1264CrossRefPubMed
7.
go back to reference Heidet L, Arrondel C, Cohen-Solal L, Forestier L, Mollet G, Guttierez B, Stavrou C, Gubler MC, Antignac MC (2001) Structure of the human type IV collagen gene COL4A3 and mutations in autosomal Alport syndrome. J Am Soc Nephrol 12:97–106PubMed Heidet L, Arrondel C, Cohen-Solal L, Forestier L, Mollet G, Guttierez B, Stavrou C, Gubler MC, Antignac MC (2001) Structure of the human type IV collagen gene COL4A3 and mutations in autosomal Alport syndrome. J Am Soc Nephrol 12:97–106PubMed
8.
go back to reference Torra R, Tazon-Vega B, Ars E, Ballarin J, (2004) Collagen type IV (α3–α4) nephropathy from isolated haematuria to renal failure. Nephrol Dial Transplant 19:2429–2432CrossRefPubMed Torra R, Tazon-Vega B, Ars E, Ballarin J, (2004) Collagen type IV (α3–α4) nephropathy from isolated haematuria to renal failure. Nephrol Dial Transplant 19:2429–2432CrossRefPubMed
9.
go back to reference Kashtan CE, Kleppel MM, Gubler MC (1996) Immunohistologic findings in Alport syndrome. in Molecular Pathology and Genetics of Alport Syndrome. Contr Nephrol Basel, Karger 117:142–153CrossRef Kashtan CE, Kleppel MM, Gubler MC (1996) Immunohistologic findings in Alport syndrome. in Molecular Pathology and Genetics of Alport Syndrome. Contr Nephrol Basel, Karger 117:142–153CrossRef
10.
go back to reference Inoue Y, Nishio H, Shirakawa T, Nekanishi K, Nakamura H, Sumino K, Nishiyama K, Iijima K, Yoshikawa N (1999) Detection of mutations in the COL4A5 gene in over 90% of patients with X-linked Alport’s syndrome by RT-PCR and direct sequencing. Am J Kidney Dis 34:854–862CrossRefPubMed Inoue Y, Nishio H, Shirakawa T, Nekanishi K, Nakamura H, Sumino K, Nishiyama K, Iijima K, Yoshikawa N (1999) Detection of mutations in the COL4A5 gene in over 90% of patients with X-linked Alport’s syndrome by RT-PCR and direct sequencing. Am J Kidney Dis 34:854–862CrossRefPubMed
11.
go back to reference Wang F, Wang YF, Ding J, Yang JY (2005) Detection of mutations in the COL4A5 gene by analyzing cDNA of skin fibroblasts. Kidney Int 67:1268–1274CrossRefPubMed Wang F, Wang YF, Ding J, Yang JY (2005) Detection of mutations in the COL4A5 gene by analyzing cDNA of skin fibroblasts. Kidney Int 67:1268–1274CrossRefPubMed
12.
go back to reference Torra R (2006) Alport syndrome and collagen IV nephropathy in Fourth Course on Genetics and renal Diseases. June 8–10, 2006, Genoa. Book of Abstracts pp 61–64 Torra R (2006) Alport syndrome and collagen IV nephropathy in Fourth Course on Genetics and renal Diseases. June 8–10, 2006, Genoa. Book of Abstracts pp 61–64
13.
go back to reference Ding J, Yang J, Liu J, Yu L (1997) Immunofluorescence study of type IV collagen alpha chains in epidermal basement membrane: application in diagnosis of X-linked Alport syndrome. Chin Med J 110:584PubMed Ding J, Yang J, Liu J, Yu L (1997) Immunofluorescence study of type IV collagen alpha chains in epidermal basement membrane: application in diagnosis of X-linked Alport syndrome. Chin Med J 110:584PubMed
14.
go back to reference Van der Loop FT, Monnens LA, Schröder CH, Lemmink HH, Breuning MH, Timmer ED, Smeets HJ (1999) Identification of COL4A5 defects in Alport’s syndrome by immunohistochemistry of skin. Kidney Int 55:1217–1224CrossRefPubMed Van der Loop FT, Monnens LA, Schröder CH, Lemmink HH, Breuning MH, Timmer ED, Smeets HJ (1999) Identification of COL4A5 defects in Alport’s syndrome by immunohistochemistry of skin. Kidney Int 55:1217–1224CrossRefPubMed
15.
go back to reference Levy M, Pirson Y, Simon P, Boudailliez B, Nivet H, Rance N, Moynot A, Broyer M, Grünfeld JP (1994) Evaluation in patients with Alport syndrome of knowledge of the disease and attitudes toward prenatal diagnosis. Clin Nephrol 42:211–220PubMed Levy M, Pirson Y, Simon P, Boudailliez B, Nivet H, Rance N, Moynot A, Broyer M, Grünfeld JP (1994) Evaluation in patients with Alport syndrome of knowledge of the disease and attitudes toward prenatal diagnosis. Clin Nephrol 42:211–220PubMed
16.
go back to reference Copelovitch L, Kaplan BS (2006) Is genetic testing of healthy pre-symptomatic children with possible Alport syndrome ethical? Pediatr Nephrol 21:455–456CrossRefPubMed Copelovitch L, Kaplan BS (2006) Is genetic testing of healthy pre-symptomatic children with possible Alport syndrome ethical? Pediatr Nephrol 21:455–456CrossRefPubMed
17.
go back to reference Proesmans W, VanDyck M (2004) Enalapril in children with Alport syndrome. Pediatr Nephrol 19:271–275CrossRefPubMed Proesmans W, VanDyck M (2004) Enalapril in children with Alport syndrome. Pediatr Nephrol 19:271–275CrossRefPubMed
18.
go back to reference Callis L, Vila A, Carrera M, Nieto J (1999) Long-term effects of cyclosporine A in Alport’s syndrome. Kidney Int 55:1051–1056CrossRefPubMed Callis L, Vila A, Carrera M, Nieto J (1999) Long-term effects of cyclosporine A in Alport’s syndrome. Kidney Int 55:1051–1056CrossRefPubMed
19.
go back to reference Chen D, Jefferson B, Harvey SJ, Zheng K, Gartley CJ, Jacobs RM, Thorner PS (2003) Cyclosporine A slows the progressive renal disease of Alpoer syndrome (X-linked hereditary nephritis): Results from a canin model. J Am Soc Nephrol 14:690–698CrossRefPubMed Chen D, Jefferson B, Harvey SJ, Zheng K, Gartley CJ, Jacobs RM, Thorner PS (2003) Cyclosporine A slows the progressive renal disease of Alpoer syndrome (X-linked hereditary nephritis): Results from a canin model. J Am Soc Nephrol 14:690–698CrossRefPubMed
21.
go back to reference Legato A, Emma F, Massella L (2006) Cyclosporine A treatment in pediatric patients with X-linked Alport syndrome : a single centre experience. Pediatr Nephrol 21:1510 (abstract COD OP 14) Legato A, Emma F, Massella L (2006) Cyclosporine A treatment in pediatric patients with X-linked Alport syndrome : a single centre experience. Pediatr Nephrol 21:1510 (abstract COD OP 14)
22.
go back to reference Heidet L, Borza DB, Jouin M, Sich M, Mattei G, Sado Y, Hudson BG, Hastie N, Antignac C, Gubler MC (2003). A human-mouse chimera of the α3α4 α5(IV) collagen protomer rescues the renal phenotype in Col4a3-/- mice. Am J Pathol 163:1633–1644CrossRefPubMedPubMedCentral Heidet L, Borza DB, Jouin M, Sich M, Mattei G, Sado Y, Hudson BG, Hastie N, Antignac C, Gubler MC (2003). A human-mouse chimera of the α3α4 α5(IV) collagen protomer rescues the renal phenotype in Col4a3-/- mice. Am J Pathol 163:1633–1644CrossRefPubMedPubMedCentral
23.
go back to reference Zeisberg M, Khurana M, Rao VH, Cosgrove D, Rougoer JP, Werner MC, Shield CF, Werb Z, Kalluri R (2006) Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease. PLoS Med 3:e100CrossRefPubMedPubMedCentral Zeisberg M, Khurana M, Rao VH, Cosgrove D, Rougoer JP, Werner MC, Shield CF, Werb Z, Kalluri R (2006) Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease. PLoS Med 3:e100CrossRefPubMedPubMedCentral
24.
go back to reference Ninichuk V, Gross O, Reichel C, Khandoga A, Pawar RD, Ciubar R, Segerer S, Belemezova E, Radomska E, Luckow B, de Lema GP, Murphy PM, Gao JL, Henger A, Kretzler M, Horuk R, Weber M, Krombach F, Schlondorff D, Anders HJ (2005) Delayed chemokine receptor 1 blockade prolongs survival in collagen 4A3-deficient mice with Alport disease. J Am Soc Nephrol 16:977–985CrossRefPubMed Ninichuk V, Gross O, Reichel C, Khandoga A, Pawar RD, Ciubar R, Segerer S, Belemezova E, Radomska E, Luckow B, de Lema GP, Murphy PM, Gao JL, Henger A, Kretzler M, Horuk R, Weber M, Krombach F, Schlondorff D, Anders HJ (2005) Delayed chemokine receptor 1 blockade prolongs survival in collagen 4A3-deficient mice with Alport disease. J Am Soc Nephrol 16:977–985CrossRefPubMed
25.
go back to reference Gross O, Koepke ML, Beirowski B, Schulze-Lohoff E, Segerer S, Weber M (2005) Nephroprotection by antifibrotic and anti-inflammatory effects of the vasopeptidase inhibitor AVE7688. Kidney Int 68:456–463CrossRefPubMed Gross O, Koepke ML, Beirowski B, Schulze-Lohoff E, Segerer S, Weber M (2005) Nephroprotection by antifibrotic and anti-inflammatory effects of the vasopeptidase inhibitor AVE7688. Kidney Int 68:456–463CrossRefPubMed
26.
go back to reference Sugimoto H, Mundel TM, Sund M, Xie L, Cosgrove D, Falluri R (2006) Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease. Proc Natl Acad Sci USA 103:7321–7326CrossRefPubMedPubMedCentral Sugimoto H, Mundel TM, Sund M, Xie L, Cosgrove D, Falluri R (2006) Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease. Proc Natl Acad Sci USA 103:7321–7326CrossRefPubMedPubMedCentral
27.
go back to reference Prodromidi EI, Poulsom R, Jeffery R, Roufosse CA, Pollard PJ, Pusey CD, Cook HT (2006) Bone marrow derived-cells contribute to podocyte regeneration and amelioration of renal disease in a mouse model of Alport syndrome. Stem Cells (24:2448–2455)CrossRefPubMed Prodromidi EI, Poulsom R, Jeffery R, Roufosse CA, Pollard PJ, Pusey CD, Cook HT (2006) Bone marrow derived-cells contribute to podocyte regeneration and amelioration of renal disease in a mouse model of Alport syndrome. Stem Cells (24:2448–2455)CrossRefPubMed
Metadata
Title
Diagnosis of Alport syndrome without biopsy?
Author
Marie Claire Gubler
Publication date
01-05-2007
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Nephrology / Issue 5/2007
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-006-0376-z

Other articles of this Issue 5/2007

Pediatric Nephrology 5/2007 Go to the issue